A stock offering by Trius Therapeutics is bringing in $34.1 million to fund research and development and other corporate expenses. Tedizolid phosphate, the firm's lead product, is being tested against severe infections such as methicillin-resistant Staphylococcus aureus.
Antibiotic company Trius secures funding for R&D
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore